Study to Evaluate the Safety of FSR Peptide Versus Placebo Following Punch Biopsy

NCT ID: NCT04473859

Last Updated: 2020-07-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 49 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-03-06
• Study Completion Date: 2009-04-28

Brief Summary

The purposes of this study is to test the safety of the study drug (FSR peptide) after a punch biopsy in healthy subjects.

Conditions

Wound Heal

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

FSR Peptide 20 μM

Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.

Group Type: EXPERIMENTAL

FSR Peptide 20μM

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Placebo

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

FSR peptide 50 μM

Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.

Group Type: EXPERIMENTAL

FSR Peptide 50μM

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Placebo

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

FSR peptide 100 μM

Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.

Group Type: EXPERIMENTAL

FSR Peptide 100μM

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Placebo

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

FSR peptide 200 μM

Each subject will have two punch biopsies. FSR peptide will be applied to one punch biopsy. Placebo will be applied to the second punch biopsy.

Group Type: EXPERIMENTAL

FSR Peptide 200μM

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Placebo

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Placebo only

Each subject will have two punch biopsies. Placebo will be applied to both punch biopsies.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Interventions

FSR Peptide 20μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention Type: DRUG

FSR Peptide 50μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention Type: DRUG

FSR Peptide 100μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention Type: DRUG

FSR Peptide 200μM

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention Type: DRUG

Placebo

Administered immediately after punch-biopsy and 24 hours after punch biopsy.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Male or female healthy subjects, 18-45 years of age and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.
• Female subjects must have been surgically sterilized at least six months prior to screening. Surgical sterilization procedures must be supported with clinical documentation made available to the sponsor and noted in the Relevant Medical History / Current Medical Conditions section of the CRF. OR: Postmenopausal women must have no regular menstrual bleeding for at least two years prior to inclusion. Menopause was to be confirmed by a plasma 17β-estradiol concentration of <20 pg/mL and a plasma FSH level of >40 IU/L.
• Normal sitting blood pressure and pulse rate , i.e.: BP: 100 - 140 mm Hg systolic, 50 - 90 mm Hg diastolic and pulse rate: 45 - 100 bpm. Blood pressure and pulse were to be measured after 3 minutes resting in a sitting position.
• Subject body mass index between 18 and 30 kg/m2
• Ability to communicate well with the investigator and comply with the requirements of the entire study.
• The subject has given his written consent to participate in the study.

Exclusion Criteria

• History of serious adverse reactions or hypersensitivity to any drug.
• Presence or history of any allergy requiring acute or chronic treatment (seasonal) allergic rhinitis which requires no treatment may be tolerated).
• History of alcohol or drug abuse in the last 3 years.
• Abnormal physical findings of clinical significance at the screening examination or baseline which would interfere with the objectives of the study.
• Need of any prescription medication within 14 days prior to the administration of the drug and/or nonprescription medication within 7 days prior to the administration of the drug or anticipated need for any concomitant medication during the study.
• Participation in a clinical trial during the previous 4 weeks, i.e. from completion of the previous trial to the planned first administration of the current trial.
• Loss of 500 ml blood or more during the 3 month period before the study, e.g. as a donor.
• Existence of any surgical or medical condition which might interfere with the distribution, metabolism or excretion of the drug, i.e. impaired renal or hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of pronounced constipation or diarrhea or conditions associated with total or partial obstruction of the urinary tract.

Symptoms of a significant somatic or mental illness in the two week period preceding drug administration.

• History of hepatitis B and / or C and / or positive serology results which indicate the presence of hepatitis B and / or C.
• Positive results from the HIV serology.
• Clinically significant abnormal laboratory values (as determined by the Principal Investigator) at the screening evaluation. Serum albumin below 3.5 g/l (Note to File no. 8 states that the correct albumin value is below 35g/l) precludes study inclusion in any case.
• History of serious mental disorders.
• Positive results of the drug screening.
• History or clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematological, neurologic or other disease.
• Presence of any active skin pathology including e.g., acne, acute sunburn, inflammatory skin disease.
• Presence of any open wounds or infection on the same arm.
• History of skin disorders e.g. atopic eczema or psoriasis or keloid reaction(s) Any condition that constitutes a contraindication to minor surgical procedures (such as bleeding disorders) or that obliges to the use of prophylactic antibiotics (such as mitral valve prolapse) or other comedications for the performance of minor surgical procedures.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Xequel Bio, Inc.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Gautam Ghatnekar

Role: PRINCIPAL_INVESTIGATOR

CEO

Locations

Swiss Pharma Contract Ltd

Allschwil, , Switzerland

Countries

Switzerland

Other Identifiers

ACT1-01

Identifier Type: -

Identifier Source: org_study_id